Nanfeng Fan
About
Nanfeng Fan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery.
According to data from OpenAlex, Nanfeng Fan has authored 22 papers receiving a total of 238 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 10 papers in Surgery. Recurrent topics in Nanfeng Fan's work include Gastric Cancer Management and Outcomes (16 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers). Nanfeng Fan is often cited by papers focused on Gastric Cancer Management and Outcomes (16 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers). Nanfeng Fan collaborates with scholars based in China, Hong Kong and France. Nanfeng Fan's co-authors include Rui‐Hua Xu, Lin Shen, Jianming Xu, Tianshu Liu, Rongbo Lin, Yi Ba, Yuxian Bai, Shukui Qin, Shunchang Jiao and Zengqing Guo and has published in prestigious journals such as Journal of Clinical Oncology, Experimental Cell Research and Frontiers in Oncology.
In The Last Decade
Nanfeng Fan
19 papers receiving 236 citations
Peers
Nanfeng Fan
Ignacio Tusquets Spain
Yuriy Ostapenko Ukraine
Sejung Park South Korea
Giuseppe Tirino Italy
Arinilda Campos Bragagnoli Brazil
E. Falcó Spain
Stephanos Pericleous United Kingdom
Ina Valeria Zurlo Italy
Meng‐Shun Sun Taiwan
Y. Y. Janjigian United States
Citations per year, relative to Nanfeng Fan Nanfeng Fan (= 1×)
peers
Ignacio Tusquets
Countries citing papers authored by Nanfeng Fan
Since
Specialization
Citations
This map shows the geographic impact of Nanfeng Fan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nanfeng Fan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nanfeng Fan more than expected).
Fields of papers citing papers by Nanfeng Fan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Nanfeng Fan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nanfeng Fan. The network helps show where Nanfeng Fan may publish in the future.
Co-authorship network of co-authors of Nanfeng Fan
This figure shows the co-authorship network connecting the top 25 collaborators of Nanfeng Fan. A scholar is included among the top collaborators of Nanfeng Fan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nanfeng Fan. Nanfeng Fan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wang, Yusheng, Wenhui Yang, Yunfeng Li, et al.. (2025). QL1203 vs placebo plus mFOLFOX6 as first-line therapy in RAS wild-type, metastatic colorectal cancer (mCRC): Interim analysis (IA) of a multicenter, randomized, double-blinded, parallel, phase 3 trial.. Journal of Clinical Oncology. 43(4_suppl). 190–190.
2.
Lin, Xiuyun, et al.. (2024). Enhanced chemotherapy response in hepatocellular carcinoma: synergistic effects of miR-122 and doxorubicin co-delivery system inducing apoptosis and DNA damage. Cancer Nanotechnology. 15(1).
3.
Zhao, Shen, Xiaofeng Li, Peicheng Lin, et al.. (2022). Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer. Frontiers in Oncology. 12. 850242–850242.
4.
Liu, Jie, et al.. (2022). The Expression Pattern of Ferroptosis-Related Genes in Colon Adenocarcinoma: Highly Correlated to Tumor Microenvironment Characteristics. Frontiers in Genetics. 13. 837941–837941.
5.
Li, Hui, et al.. (2021). CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism. Experimental Cell Research. 409(1). 112892–112892.
6.
Zhao, Shen, Nanfeng Fan, Hui Li, et al.. (2020). Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study. Annals of Translational Medicine. 8(19). 1233–1233.
7.
Peng, Zhi, Tianshu Liu, Jia Wei, et al.. (2020). A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.. Journal of Clinical Oncology. 38(15_suppl). 4560–4560.
8.
Lin, Rongbo, Hui Li, Jinfeng Zhu, et al.. (2019). FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) as a first-line treatment in advanced gastric cancer (AGC): A multicenter, randomized phase II trial, FNF-004 trial.. Journal of Clinical Oncology. 37(4_suppl). 6–6.
9.
Xu, Rui‐Hua, Zhi‐Qiang Wang, Lin Shen, et al.. (2019). S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.. Journal of Clinical Oncology. 37(15_suppl). 4017–4017.
10.
Lin, Rongbo, Jinfeng Zhu, Peicheng Lin, et al.. (2019). POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial.. Journal of Clinical Oncology. 37(15_suppl). 4035–4035.
11.
Li, Jin, Rui‐Hua Xu, Shukui Qin, et al.. (2018). Aflibercept Plus Folfiri in Asian Patients with Pretreated Metastatic Colorectal Cancer: A Randomized Phase III Study. Future Oncology. 14(20). 2031–2044.
12.
Lin, Rongbo, Shen Zhao, Hui Li, Jie Liu, & Nanfeng Fan. (2017). A phase II Study of FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel) plus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): A feasibility analysis.. Journal of Clinical Oncology. 35(4_suppl). 56–56.
13.
Lin, Rongbo, Shen Zhao, Hui Li, Jie Liu, & Nanfeng Fan. (2017). A pilot study of apatinib reversing paclitaxel resistance in heavily pretreated advanced gastric cancer (AGC).. Journal of Clinical Oncology. 35(4_suppl). 89–89.
14.
Wang, Jinwan, Rui‐Hua Xu, Jian Li, et al.. (2015). Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer. 19(1). 234–244.
15.
Lin, Rongbo, Nanfeng Fan, Ying Chen, et al.. (2014). A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer. Journal of Chemotherapy. 27(1). 52–56.
16.
Shi, Chunmei, et al.. (2011). Retrospective Analysis of Adjuvant Intraperitoneal Chemotherapy Effect Prognosis of Resectable Gastric Cancer. Oncology. 80(5-6). 289–295.
17.
Chen, Qiang, Rongbo Lin, Yunbin Ye, et al.. (2009). The combined administration of partially HLA-matched irradiated allogeneic lymphocytes and thalidomide in advanced renal-cell carcinoma: a case report. Medical Oncology. 27(2). 554–558.
18.
Lin, Rongbo, Nanfeng Fan, Ling Chen, & Jie Liu. (2009). Chemoimmunotherapy of chemotherapy-refractory metastatic colorectal cancer with gemcitabine plus FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2. World Chinese Journal of Digestology. 17(32). 3346–3346.
19.
Lin, Rongbo, Nanfeng Fan, Zengqing Guo, et al.. (2008). A Phase II Study of 5-Fluorouracil/Leucovorin in Combination with Paclitaxel and Oxaliplatin as First-Line Treatment for Patients with Advanced Gastric Cancer. Journal of Chemotherapy. 20(6). 744–748.
20.
Yang, Jianwei, Nanfeng Fan, Zengqing Guo, et al.. (2005). [A randomized controlled trail of taxol-based combination regimens for advanced gastric cancer].. PubMed. 24(12). 1531–6.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ignacio Tusquets Breakdown of academic impact, for papers by Yuriy Ostapenko Breakdown of academic impact, for papers by Sejung Park Breakdown of academic impact, for papers by Giuseppe Tirino Breakdown of academic impact, for papers by Arinilda Campos Bragagnoli Breakdown of academic impact, for papers by E. Falcó Breakdown of academic impact, for papers by Stephanos Pericleous Breakdown of academic impact, for papers by Ina Valeria Zurlo Breakdown of academic impact, for papers by Meng‐Shun Sun Breakdown of academic impact, for papers by Y. Y. Janjigian